-
Lonafarnib, sold
under the
brand name Zokinvy, is a
medication used to
reduce the risk of
death due to Hutchinson-Gilford
progeria syndrome and for the...
-
syndrome In
November 2020, the U.S. Food and Drug
Administration approved lonafarnib,
which helps prevent buildup of
defective progerin and
similar proteins...
-
causing the
rapid aging effects you see in HGPS.
Researchers are
exploring lonafarnib (a
farnesyltransferase inhibitor) as a
potential pharmacological therapy...
- coated". dailymed.nlm.nih.gov.
Retrieved 2021-07-01. "DailyMed - ZOKINVY-
lonafarnib capsule". dailymed.nlm.nih.gov.
Retrieved 2021-07-01. "DailyMed - DUPIXENT-...
-
others have
entered clinical trials for
different cancers. SCH66336 (
Lonafarnib) was the
first to do so,
followed by R115777 (Zarnestra, Tipifarnib)....
- of progeria, and in May 2007 a
phase II
clinical trial using the FTI
lonafarnib was
started for
children with progeria. In
signal transduction via G protein...
-
lomifylline (INN)
lomitapide (USAN, INN)
Lomotil (Pfizer)
lomustine (INN)
lonafarnib (USAN)
lonapalene (INN)
lonaprisan (USAN)
lonaprofen (INN)
lonazolac (INN)...
-
research purposes. As a
result of this programme, an
experimental drug,
Lonafarnib, a
transferase inhibitor, was
developed that
might be able to slow down...
-
activation of anti-viral cell
mediated immunity. The
prenylation inhibitor lonafarnib prevents hepatitis D
viral particle ****embly by
inhibiting the farnesylation...
- In 2020 the
American Food and Drug
Administration approved the use of
lonafarnib in
children with the
disease based on
research and
funding provided by...
